secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2024-02-12T23:59:59+00:00
Accession:  0000950170-24-013568
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acasti Pharma Q3 FY2024 net loss narrows to $2.4M; cash runway extends to early 2026
--------------------------------------------------------------------------------

- Net loss of $2.4M ($0.21/share) vs $3.9M ($0.52) in prior-year quarter.
- R&D expenses decreased 44% YoY to $1.4M due to resource prioritization on GTX-104.
- Cash, equivalents and ST investments $25.1M; runway extended into 2nd calendar Q 2026.
- Pivotal STRIVE-ON Phase 3 trial enrollment ongoing; NDA submission on track for 1H 2025.
- Company secured $7.5M private placement in prior quarter to bolster balance sheet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000095017024013568/0000950170-24-013568-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000095017024013568/acst-20240212.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-013568

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer